BR112020007880A2 - receptor de células t - Google Patents

receptor de células t Download PDF

Info

Publication number
BR112020007880A2
BR112020007880A2 BR112020007880-8A BR112020007880A BR112020007880A2 BR 112020007880 A2 BR112020007880 A2 BR 112020007880A2 BR 112020007880 A BR112020007880 A BR 112020007880A BR 112020007880 A2 BR112020007880 A2 BR 112020007880A2
Authority
BR
Brazil
Prior art keywords
tcr
cell
clone
cells
cancer
Prior art date
Application number
BR112020007880-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Sewell
Garry DOLTON
Original Assignee
University College Cardiff Consultants Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd. filed Critical University College Cardiff Consultants Ltd.
Publication of BR112020007880A2 publication Critical patent/BR112020007880A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112020007880-8A 2017-10-26 2018-10-22 receptor de células t BR112020007880A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1717578.7 2017-10-26
GBGB1717578.7A GB201717578D0 (en) 2017-10-26 2017-10-26 Novel T-cell receptor
GB1806155.6 2018-04-16
GBGB1806155.6A GB201806155D0 (en) 2017-10-26 2018-04-16 Novel t-cell receptor
PCT/GB2018/053045 WO2019081902A1 (en) 2017-10-26 2018-10-22 NEW LYMPHOCYTE RECEPTOR T

Publications (1)

Publication Number Publication Date
BR112020007880A2 true BR112020007880A2 (pt) 2020-10-27

Family

ID=60580240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020007880-8A BR112020007880A2 (pt) 2017-10-26 2018-10-22 receptor de células t

Country Status (17)

Country Link
US (2) US11725039B2 (cg-RX-API-DMAC7.html)
EP (2) EP3700925B8 (cg-RX-API-DMAC7.html)
JP (1) JP7289311B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200078497A (cg-RX-API-DMAC7.html)
CN (1) CN111278855B (cg-RX-API-DMAC7.html)
AU (2) AU2018356944A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077635A1 (cg-RX-API-DMAC7.html)
DK (1) DK3700925T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091015A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907819T3 (cg-RX-API-DMAC7.html)
GB (2) GB201717578D0 (cg-RX-API-DMAC7.html)
IL (1) IL274025A (cg-RX-API-DMAC7.html)
MX (1) MX2020004334A (cg-RX-API-DMAC7.html)
PL (1) PL3700925T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202002537WA (cg-RX-API-DMAC7.html)
WO (1) WO2019081902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
EP4090969A1 (en) * 2020-01-16 2022-11-23 Universität Basel Mr1 ligands and pharmaceutical compositions for immunomodulation
WO2021250511A1 (ko) * 2020-06-10 2021-12-16 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도
WO2022099297A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Multiplexed engineered ipsc and immune effector cells targeting solid tumors
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022244876A1 (ja) * 2021-05-20 2022-11-24 慶應義塾 抗腫瘍剤
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
AU2018231405B2 (en) * 2017-03-07 2024-02-08 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor

Also Published As

Publication number Publication date
PL3700925T3 (pl) 2022-05-02
GB201806155D0 (en) 2018-05-30
US20210147506A1 (en) 2021-05-20
SG11202002537WA (en) 2020-05-28
AU2018356944A1 (en) 2020-04-16
AU2024202735A1 (en) 2024-05-30
JP7289311B2 (ja) 2023-06-09
US20200369742A1 (en) 2020-11-26
CA3077635A1 (en) 2019-05-02
CN111278855B (zh) 2024-04-02
IL274025A (en) 2020-06-30
US11725039B2 (en) 2023-08-15
MX2020004334A (es) 2020-08-03
EP4039700A1 (en) 2022-08-10
ES2907819T3 (es) 2022-04-26
EP3700925B1 (en) 2021-12-29
GB201717578D0 (en) 2017-12-13
WO2019081902A1 (en) 2019-05-02
JP2021500406A (ja) 2021-01-07
EP3700925B8 (en) 2022-02-16
EA202091015A1 (ru) 2020-07-17
DK3700925T3 (en) 2022-04-04
KR20200078497A (ko) 2020-07-01
US11078252B2 (en) 2021-08-03
CN111278855A (zh) 2020-06-12
EP3700925A1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
US11078252B2 (en) T-cell receptor
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
AU2023282185B2 (en) Methods of isolating T cell receptors having antigenic specificity for a cancer specific mutation
TWI764886B (zh) 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
TWI826891B (zh) 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
JP2021151248A (ja) T細胞レセプター
CN109468278A (zh) 基因工程化的t细胞及应用
EP3914270A1 (en) Compositions and methods for targeting mutant ras
Matsuzaki et al. A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
CN111372944A (zh) 新型γδT细胞受体和其配体
TWI790162B (zh) 新穎t細胞受器及使用其之免疫治療
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
JP2025525382A (ja) Magea4特異的t細胞受容体
HK40034405A (en) Novel t-cell receptor
HK40034405B (en) Novel t-cell receptor
EA045252B1 (ru) Новый т-клеточный рецептор
Rosenberger Comparing the therapeutic potential of T cell receptors from tumors and healthy donors for adoptive T cell therapy in cancer
HK40099489A (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN121586583A (zh) 包含并表达自噬正调节因子的经修饰人淋巴细胞
CN119604524A (zh) 用于癌症疗法的工程化t细胞受体构建体
Morgan Cancer Immunotherapy: Chapter 17. Adoptive T-cell Therapy: Engineering T-cell Receptors

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2853 DE 09-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.